Cardiff Oncology Reports Third Quarter 2023 Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Cardiff Oncology, Inc. (CRDF) Tops Q3 EPS by 6c
November 2, 2023 4:21 PM EDTCardiff Oncology, Inc. (NASDAQ: CRDF) reported Q3 EPS of ($0.22), $0.06 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $141 thousand versus the consensus estimate of $61.6 thousand.
For earnings history and earnings-related data on Cardiff Oncology, Inc. (CRDF) click here.
... More